

AMENDMENTS

Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1. (Withdrawn) A method for treating a lupus patient characterized by the presence of anti-dsDNA comprising administering to the patient a therapeutic composition in pharmaceutically acceptable carrier for administration to a patient selected from the group consisting of peptides having sequence identity with ribosomal protein S1 which are immunoreactive with anti-dsDNA and anti-idiotypic antibody or antibody fragments immunoreactive with anti-dsDNA antibodies.
2. (Withdrawn) The method of claim 1 wherein the peptide is between four and forty amino acids in length.
3. (Withdrawn) The method of claim 1 wherein the peptide is conjugated to a carrier molecule or is a fusion protein.
4. (Canceled)
5. (Withdrawn) The method of claim 1 wherein the composition is anti-idiotypic antibody immunoreactive with anti-dsDNA antibody.
6. (Withdrawn) The method of claim 5 wherein the antibody is administered in a dosage effective to kill anti-dsDNA antibody producing cells.
7. (Withdrawn) The method of claim 5 wherein the antibody is administered in a dosage effective to decrease the amount of anti-dsDNA antibody levels in the patient.

8. (Currently amended) A therapeutic composition in a pharmaceutically acceptable carrier for administration to a human patient having anti-dsDNA antibodies comprising single chain anti-idiotypic Fv antibody fragments immunoreactive with anti-dsDNA human antibodies isolated from SLE patients.

9. (previously presented) The compositions of claim 8 wherein the anti-idiotypic antibody fragments are derived from human antibody.

10. (previously presented) The composition of claim 8 wherein the anti-idiotypic antibody fragments are conjugated to a carrier molecule or is a fusion protein.

11. (previously presented) The composition of claim 8 wherein the composition is a peptide administered to a patient in an amount effective to induce tolerance.

12. (previously presented) The composition of claim 8 wherein the composition comprises an anti-idiotypic antibody fragment derived from an anti-idiotypic antibody immunoreactive with anti-dsDNA antibody.

13. (previously presented) The composition of claim 12 wherein the anti-idiotypic antibody is administered in a dosage effective to kill anti-dsDNA antibody producing cells.

14. (previously presented) The composition of claim 12 wherein the anti-idiotypic antibody is administered in a dosage effective to decrease the amount of anti-dsDNA antibody levels in the patient.

15. (previously presented) The composition of claim 8 wherein the anti-idiotypic antibody is a single-chain Fv fragment.